NCT00534248View on ClinicalTrials.gov

Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)

PHASE3CompletedINTERVENTIONAL

Enrollment

22,439

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

Shingles

Interventions

BIOLOGICAL

Zoster Vaccine, Live (Zostavax™)

A single dose 0.65 ml Zostavax™ (Live, attenuated Zoster Vaccine) was administered by subcutaneous injection on Day 1.

BIOLOGICAL

Comparator: Placebo

A single dose of 0.65 ml Placebo (A vaccine stabilizer of Zostavax™ with no live virus) was administered by subcutaneous injection on Day 1.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00534248 - Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022) | Biotech Hunter | Biotech Hunter